any deep pocket can come in and initiate a massive squeeze and make huge profits. But alot of these guys need substantial evidence to have strong sells. 100% this will happen if the sells # are adequate.
Thus, a great portion of that 82 mil will cover and sit on the sideline. Logic tells me that it is too much of a risk to go through the launch, if the shorts aren't big enough to stomach the upside.
deep pockets don't have to cover now, but out of 82 mil shares, how many are retail shorts or small institutions that can't afford the loss? Agree, big institutions can pay for news before they are released and they can cover and even buy all the shares they want within days. But of the 82 mil shares, a great portion of that are NON-deep pockets riding the coatails of the big guys, and they will suffer if they don't use some strategy. LIke you said, they will go broke because the upside is without limit.
agree 100% with what you are saying. But also there is some degree of strategy and stubborness in them. They began shorting before the FDA decision, which indicated that they were very certain that AFrezza would get rejected. But instead got approval, so they were stuck with 70 + million shares shorted. They couldn't cover back then because they knew they would have 4-6 months of silent period.
So now the question is: how many of them are willing to hold their position in face of a possible epic blockbuster sell? They know the potential of Afrezza is there. If it is a major blockbuster, yes they will have a huge loss before they can buy into it. Or will they cover now and wait for the sells # to resume a position. The upside is without limit, hence covering a short position may suffer a huge loss. The downside is very limited, if Afrezza flops. Thus, if I was strategic and logical, I would cover before it gets out of control. I expect most to cover before the launch.
Asia has no controlling governmental FDA like entity; US FDA approved drugs are gold standards for them. Isreal, I am guessing is the same as most Asian countries, relying on Euro or US governmental bodies.
Talking about perfect time, IPO of his new company EYES, at the same time afrezza is getting advertisement and launch.
these shorts are finally getting a taste of their own medicine. Squeeze and they are out of shares to shorts, but up to their necks with shares to cover. $20 before launch.
u see the glass half empty, and everyone else sees half full---that is why you are a short. Sure SNY can always walk out if they can't match the price offered by another company.
i think what it implies is that SNY has 30 days to counter offer. WE need to see the offer first before we get excited. Given Al's age, I think he is selling everytghing piece by piece. But this gets very complicated, SNY owns 65% of Afrezza, company B owns technosphere and 35% of Afrezza. But what about mnkd shares, how do they determine the price? Maybe this is why they needed Deerfield.
The fact that this is heavily shorted. A deep pocket can come in and buy this to the stratosphere, scaring off the shorts to cover in panic. How the deep pocket can pull this off is simply mnkd is dirt cheap, with many possible scenarios that could sky rocket: 1) BO 2) Technosphere deals 3) Sanofi revenue guidance.
their phones and emails are monitored by FBI and sec/exchange. The articles are their communication routes. Tell that to the sec and exchange when you write a complaint.
no need to tell you anything, your ignorance and stupidity already told you to short this stock. Thus, my advice is to keep on shorting. LOL. We need more fuel for the rally during the holidays and beyond.
I suspected that the conference would be a non-issue; management has been down playing since FDA approval. They want to help out Sanofi accumulating cheap shares, so that Sanofi would be deeply tied and buyout will happen.
easy tracking, hire some computer wizz, track down his IP address which would locate him to his work, resident, and associates.
that would be something to talk about, a slim ball money manager downgrades a company and spends all his waking moment on YMB bashing the company. This definately deserves an award winning journalism work.
i can't find a single reason not to buy mnkd now. the potential is unlimited baggers.